Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (848)	2/22/2005 3:08:14 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

In early February, PFE had great news on their SU11248 molecule Yes, the news on Feb.11 about the EMA granting PFE ODS for SU11248 for gastric Ca resistant to gleevec, was a good one, and although the stock that day had what seemed an "unimpressive day" since it closed at 25.16 (below the O at 25.30) and on moderate volume of 24,738,000 however, that was the day the stock started on its present near term uptrend.<g> The nearest support remains now at 25.88 to 25.90 and resistance at yesterday's H of 27.75 and then the Dec.16 H at 29.10 bigcharts.marketwatch.com The stock has already closed its Dec.17 down-gap which was made on an impressive volume of 289,713,792 However, in spite of the significant down-gap, the stock was able to close that day at 25.75 above its O of 25.10 <g> PFE has announced that it is going to trim some of its general sales and marketing expenses, which have been running at more than 2x its R&D expenses.That means, among other things,that it is going to cut down some on "sales representatives" (in some cases there were as many as 3 visiting the same doctor)and cut some of the invitations and other perks to doctors (I miss some of those since I retired more than 5 yrs. ago.<g>) PFE also seems to have a much lesser exposure to the potential losses from class action litigation (Some people have estimated MRK's potential loss on that regard to as much as $50Bs.<g>)And I don't know how much help having a "warning" on the label is going to be, since the tobacco companies had that in the packs and advertisements for some time and apparently it wasn't that much of a big hurdle for the trial lawyers to jump over.<g> On its monthly chart, PFE is still on the down-trend coming from its Feb.2004 H at 38.89 and I hope it will not have to retest its Dec,17 L of 21.99 bigcharts.marketwatch.com RAGL Bernard